Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen picks up AC Immune's Alzheimer's vaccine

This article was originally published in Scrip

Executive Summary

AC Immune has signed a license agreement with Johnson and Johnson subsidiary Janssen, worth a potential $509m, to develop its Alzheimer's disease vaccine candidates.

You may also be interested in...



J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration

Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.

Grifols-Backed Biotech Sees Early Promise With Alzheimer's Vaccine

Phase I results for Araclon Biotech's Alzheimer's disease vaccine, ABvac40 – the only vaccine data presented at this year's Alzheimer's Association International Conference – warrant further exploration of this innovative approach to the disease.

2020 Vision For Biopharma

Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027485

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel